Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) EBIT Margin (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed EBIT Margin for 4 consecutive years, with 270.24% as the latest value for Q4 2025.

  • Quarterly EBIT Margin rose 8414.0% to 270.24% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 50.81% through Dec 2025, down 3054.0% year-over-year, with the annual reading at 50.81% for FY2025, 3054.0% down from the prior year.
  • EBIT Margin for Q4 2025 was 270.24% at bioAffinity Technologies, up from 158.56% in the prior quarter.
  • The five-year high for EBIT Margin was 270.24% in Q4 2025, with the low at 169160.69% in Q1 2023.
  • Average EBIT Margin over 4 years is 25721.21%, with a median of 158.56% recorded in 2025.
  • The sharpest move saw EBIT Margin skyrocketed 16907986bps in 2024, then crashed -11108bps in 2025.
  • Over 4 years, EBIT Margin stood at 69213.17% in 2022, then surged by 100bps to 105.83% in 2023, then soared by 276bps to 186.11% in 2024, then skyrocketed by 45bps to 270.24% in 2025.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 270.24%, 158.56%, and 198.16% for Q4 2025, Q3 2025, and Q2 2025 respectively.